Cartesian Therapeutics

Cartesian Therapeutics EBITDA per Share

The EBITDA per Share of Cartesian Therapeutics (RNAC) as of Oct 16, 2026 is -3.34 USD. In the previous year, EBITDA per Share was -1.69 USD — a change of 97.02% (lower).

EBITDA per Share

-3.34USD

YoY

97.02%

Last updated:

EBITDA per Share of Cartesian Therapeutics is 2025 -3.34 USD. EBITDA per Share of Cartesian Therapeutics was 2024 -1.69 USD. It decreases by 97.02% lower compared to the previous year.

The Cartesian Therapeutics EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2018
-102.38 USD
Jan 1, 2019
-37.04 USD
Jan 1, 2020
-22.47 USD
Jan 1, 2021
-1.79 USD
Jan 1, 2022
3.64 USD
Jan 1, 2023
-16.71 USD
Jan 1, 2024
-1.69 USD
Jan 1, 2025
-3.34 USD
The Cartesian Therapeutics EBITDA per Share history
YEAREBITDA per ShareYoY
-3.34USD+97.02%
-1.69USD-89.86%
-16.71USD-559.05%
3.64USD-303.26%
-1.79USD-92.03%
-22.47USD-39.33%
-37.04USD-63.82%
-102.38USD-1.22%
-103.65USD+50.44%
-68.89USD+3,403.66%
-1.97USD-95.44%
-43.08USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cartesian Therapeutics Stock analysis

What does Cartesian Therapeutics do? Cartesian Therapeutics Inc, trading under the ticker RNAC, is a biotechnology company based in Watertown, United States. The company has 75 employees and went public via an IPO on June 22, 2016. Cartesian Therapeutics operates within the Health Care sector, specifically in the Biotechnology industry. The company's website is https://selectabio.com/. Cartesian Therapeutics focuses on developing therapeutic solutions, though specific product names or clinical stage details are not provided in the available information. The company's headquarters are located in Watertown, and it is engaged in research and development activities typical of a biopharmaceutical firm. Cartesian Therapeutics is identified by its ISIN number US8162123025. The company's activities are centered around advancing biotechnology for healthcare applications, with a focus on innovative therapeutic approaches. The company's operational scope and specific research areas are not detailed beyond the general biotechnology sector focus. Cartesian Therapeutics is a clinical-stage biopharmaceutical company, though the exact stage of clinical development for any specific therapy is not specified in the provided data. The company's website serves as a primary source of information for further details on its operations and developments. Cartesian Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cartesian Therapeutics stock

EBITDA per Share of Cartesian Therapeutics is -3.34 USD in 2025.

EBITDA per Share of Cartesian Therapeutics changed from -1.69 USD to -3.34 USD, representing a 97.02% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Cartesian Therapeutics since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Cartesian Therapeutics

All Key Metrics — Cartesian Therapeutics